I have an avocado oil spray bottle. I do not know what tallow is. A 50-year-old dude reads the actual research on seed oils, dairy, and the latest dietary advice cycle — and reports what the evidence says you should put in your frying pan.
Lilly’s retatrutide just delivered bariatric-equivalent weight loss in Phase 3. The numbers, why the low dose is the real story, and the gray-market reality that got there first.
I was diagnosed with anxiety in 2021, hit 373 lbs in 2024, and started TRT in 2025. The full story, the numbers, and what the discourse misses.
Your cholesterol panel at 50, decoded. The six numbers, the new 2026 guideline targets, the coronary calcium scan, and what the drugs actually do.
I am at goal weight on Zepbound. SURMOUNT-MAINTAIN is the trial I have been waiting for. Here is what holding the line at a lower dose actually looks like.
A study of 479,000 adults found cyclists had 22% lower Alzheimer’s risk, 40% lower young-onset dementia risk, and measurably larger hippocampi than nonactive controls. Here’s what the data actually shows, the APOE caveat the headlines missed, and the negative RCT you should hold next to it.
In May 2026, three major papers landed on Lp(a) — the genetic cholesterol marker that 1 in 5 adults carry at risk levels and almost nobody gets tested for. Here’s what the new evidence says, what to do if your number is high, and the aspirin advice you should stop following.
I knew statins worked. I did not know how strange the origin story was. How statins started with mold The first statin came from Akira Endo, a Japanese biochemist who grew up fascinated by fungi and was inspired by the discovery of penicillin. After spending time in New York in the 1960s, he was struck
If you have Medicare and your doctor has been telling you about a new daily pill for weight loss, this post is for you. Foundayo is real, it’s FDA-approved, and starting July 1, 2026, it’s covered for $50 a month under Medicare’s GLP-1 Bridge program for eligible beneficiaries. This is genuinely new. Foundayo got FDA
Starting July 1, 2026, Medicare will cover Wegovy, Zepbound and Foundayo for obesity at a $50 monthly copay. The program is real, it’s called the Medicare GLP-1 Bridge, and it runs through December 31, 2027. I’m lucky — my employer’s insurance covers Zepbound, and I’ve been on it long enough to learn the system the
